Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aldeyra Therapeutics (ALDX) shares

Learn how to easily invest in Aldeyra Therapeutics shares.

Aldeyra Therapeutics is a biotechnology business based in the US. Aldeyra Therapeutics stocks (ALDX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $11.47 – an increase of 0.31% over the previous week. Aldeyra Therapeutics employs 11 staff and has a market cap (total outstanding stock value) of $188.8 million.

How to buy shares in Aldeyra Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ALDX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aldeyra Therapeutics stock price (NASDAQ:ALDX)

Use our graph to track the performance of ALDX stocks over time.

Aldeyra Therapeutics shares at a glance

Information last updated 2022-01-23.
Latest market close$3.26
52-week range$3.00 - $15.95
50-day moving average $5.96
200-day moving average $9.12
Wall St. target price$20.40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.08

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Aldeyra Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Aldeyra Therapeutics price performance over time

Historical closes compared with the close of $3.26 from 2022-01-27

1 week (2022-01-19) -7.91%
1 month (2021-12-29) -18.70%
3 months (2021-10-26) -59.30%
6 months (2021-07-29) -63.86%
1 year (2021-01-29) -70.89%
2 years (2020-01-29) -41.47%
3 years (2019-01-29) 8.46
5 years (2017-01-27) 5.9

Aldeyra Therapeutics financials

Gross profit TTM $0
Return on assets TTM -18.76%
Return on equity TTM -36.92%
Profit margin 0%
Book value $3.78
Market capitalisation $188.8 million

TTM: trailing 12 months

Aldeyra Therapeutics share dividends

We're not expecting Aldeyra Therapeutics to pay a dividend over the next 12 months.

Aldeyra Therapeutics share price volatility

Over the last 12 months, Aldeyra Therapeutics's shares have ranged in value from as little as $3 up to $15.95. A popular way to gauge a stock's volatility is its "beta".

ALDX.US volatility(beta: 1.52)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aldeyra Therapeutics's is 1.521. This would suggest that Aldeyra Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aldeyra Therapeutics overview

Aldeyra Therapeutics, Inc. , a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site